RESEARCH TRIANGLE PARK, N.C. – April 30, 2015 – Quintiles, the world’s largest biopharmaceutical services company, has been named to the InformationWeek Elite 100, a ranking of the top business technology innovators in the U.S.
In compiling the InformationWeek Elite 100, the publication tracks the technology-based investments, strategies and results of some of the best-known organizations in the country. Unique among corporate rankings, the Elite 100 spotlights the power of business technology innovation. Quintiles was previously named to the InformationWeek 500 for five consecutive years.
Accelerating the Clinical Trial Process: Quintiles Infosario® Site Targeting
Quintiles was named to the 2015 InformationWeek Elite 100 for its innovative Quintiles Infosario Site Targeting application which takes a patient-centric approach to clinical trial recruitment. The app identifies a virtual patient cohort using billions of data elements collected from de-identified electronic health records (EHRs). The cohort is then compared against clinical trial criteria and Quintiles’ global investigator/researcher database to quickly identify research sites which are currently treating eligible patients.
The app is ‘data agnostic’ and can analyze multiple EHRs assessing patients with common conditions such as asthma and heart disease, as well as records from specialty physician groups and hospitals who treat less common, more complex conditions such as multiple myeloma or hemophilia.
“Having a holistic understanding of patients and their treatment in a real-world setting is critical in research,” said Angie Hill, PharmD, senior director, Quintiles Technology Solutions. “The app provides a data bridge across research and healthcare leading to actionable patient insights streamlining clinical trial design and delivery.”
While insights about real patients have many applications, there also exists the practical need to locate patients meeting criteria and enroll them into clinical trials. The app achieves this by pivoting within the data to focus on the practitioners treating these patients, creating instant and actionable schedules of clinical trial investigators with the right therapeutic experience.
“We are honored that Quintiles has been named to the Elite 100,” said Richard Thomas, president, Quintiles Technology & Solutions. “We have a very talented team at Quintiles that always goes above and beyond in search of solutions to industry challenges. The Elite 100 accolade recognizes their innovation and leadership creating next generation digital platforms such as Infosario Site Targeting.”
InformationWeek Editor Chris Murphy said the InformationWeek Elite 100 spotlights companies at which IT is not only inseparable from every department, but is pivotal to every customer experience. "Gone are the day's IT could run as an entity unto itself,” Murphy explained. “If IT isn't part of product development, or marketing, or customer service, your company risks falling behind in the era of digital business.
“At InformationWeek, we talk about this as 'IT Without Borders,' as we see the best IT leaders tearing down traditional borders to help every department leverage technologies such as data analytics, the cloud, and mobility.”
Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 33,000 employees conducting business in approximately 100 countries, we helped develop or commercialize all of 2014’s top-75 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.
Phil Bridges, Media Relations (email@example.com)
+ 1.919.998.1653 (office) +1.919.457.6347 (mobile)
Todd Kasper, Investor Relations (InvestorRelations@quintiles.com)